Novel Simulation Model of Non-Muscle Invasive Bladder Cancer

A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients

Sanjay R Patel, Tuan Dinh, Joyce Noah-Vanhoucke, Badri Rengarajan, Kevin Mayo, Peter E Clark, Ashish M Kamat, Cheryl T Lee, Wade J Sexton, Gary D Steinberg

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Introduction: There have been no randomized controlled trials (RCTs) evaluating the clinical or economic benefit of mitomycin C intravesical therapy vs. radical cystectomy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). We used the Archimedes computational model to simulate RCT comparing radical cystectomy versus intravesical mitomycin C (MMC) therapy to evaluate the clinical and economic outcomes for BCG-refractory NMIBC as well demonstrate the utility of computer based models to simulate a clinical trial. Methods: The Archimedes model was developed to generate a virtual population using the Surveillance Epidemiology and End Results database, other clinical trials, and expert opinions. Patients selected were diagnosed with NMIBC (<cT2 disease) who recurred or progressed despite BCG therapy and were randomized to 1) immediate radical cystectomy vs. 2) MMC induction intravesical therapy. Clinical (progression, overall survival, and disease specific survival) and economic outcomes were reported. Results: A total of 1300 virtual patients were evaluation. Progression to MIBC in the MMC treatment arm was 30% over the lifetime. Disease specific death at 5 years was 1.6% and 8.7% for the immediate cystectomy and MMC treatment arms respectively; while, overall death was 17.8% and 23.8% at 5 years. Over a 5-year period the average cost of immediate cystectomy was $64,675 vs $68,517 in the MMC arm. Conclusion: Immediate radical cystectomy after BCG failure for NMIBC has improved survival and is more cost-effective when compared to those undergoing MMC. Simulation of clinical trials using computational models similar to the Archimedes model can overcome shortcomings of real-world clinical trials and may prove useful in the face of current medical cost-conscious era.

OriginalsprogEngelsk
TidsskriftBladder cancer (Amsterdam, Netherlands)
Vol/bind1
Udgave nummer2
Sider (fra-til)143-150
ISSN2352-3727
DOI
StatusUdgivet - 2015
Udgivet eksterntJa

Fingeraftryk

Cystectomy
Mitomycin
Mycobacterium bovis
Clinical Trials
Randomized Controlled Trials
Population Surveillance
Expert Testimony
Conservative Treatment
Computer Simulation
Epidemiology
Databases

Citer dette

Patel, Sanjay R ; Dinh, Tuan ; Noah-Vanhoucke, Joyce ; Rengarajan, Badri ; Mayo, Kevin ; Clark, Peter E ; Kamat, Ashish M ; Lee, Cheryl T ; Sexton, Wade J ; Steinberg, Gary D. / Novel Simulation Model of Non-Muscle Invasive Bladder Cancer : A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. I: Bladder cancer (Amsterdam, Netherlands). 2015 ; Bind 1, Nr. 2. s. 143-150.
@article{0496d4a2ea6c4bad8e00291c4e60e083,
title = "Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients",
abstract = "Introduction: There have been no randomized controlled trials (RCTs) evaluating the clinical or economic benefit of mitomycin C intravesical therapy vs. radical cystectomy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). We used the Archimedes computational model to simulate RCT comparing radical cystectomy versus intravesical mitomycin C (MMC) therapy to evaluate the clinical and economic outcomes for BCG-refractory NMIBC as well demonstrate the utility of computer based models to simulate a clinical trial. Methods: The Archimedes model was developed to generate a virtual population using the Surveillance Epidemiology and End Results database, other clinical trials, and expert opinions. Patients selected were diagnosed with NMIBC (",
author = "Patel, {Sanjay R} and Tuan Dinh and Joyce Noah-Vanhoucke and Badri Rengarajan and Kevin Mayo and Clark, {Peter E} and Kamat, {Ashish M} and Lee, {Cheryl T} and Sexton, {Wade J} and Steinberg, {Gary D}",
year = "2015",
doi = "10.3233/BLC-150020",
language = "English",
volume = "1",
pages = "143--150",
journal = "Bladder cancer (Amsterdam, Netherlands)",
issn = "2352-3727",
publisher = "IOS Press",
number = "2",

}

Novel Simulation Model of Non-Muscle Invasive Bladder Cancer : A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. / Patel, Sanjay R; Dinh, Tuan; Noah-Vanhoucke, Joyce; Rengarajan, Badri; Mayo, Kevin; Clark, Peter E; Kamat, Ashish M; Lee, Cheryl T; Sexton, Wade J; Steinberg, Gary D.

I: Bladder cancer (Amsterdam, Netherlands), Bind 1, Nr. 2, 2015, s. 143-150.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Novel Simulation Model of Non-Muscle Invasive Bladder Cancer

T2 - A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients

AU - Patel, Sanjay R

AU - Dinh, Tuan

AU - Noah-Vanhoucke, Joyce

AU - Rengarajan, Badri

AU - Mayo, Kevin

AU - Clark, Peter E

AU - Kamat, Ashish M

AU - Lee, Cheryl T

AU - Sexton, Wade J

AU - Steinberg, Gary D

PY - 2015

Y1 - 2015

N2 - Introduction: There have been no randomized controlled trials (RCTs) evaluating the clinical or economic benefit of mitomycin C intravesical therapy vs. radical cystectomy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). We used the Archimedes computational model to simulate RCT comparing radical cystectomy versus intravesical mitomycin C (MMC) therapy to evaluate the clinical and economic outcomes for BCG-refractory NMIBC as well demonstrate the utility of computer based models to simulate a clinical trial. Methods: The Archimedes model was developed to generate a virtual population using the Surveillance Epidemiology and End Results database, other clinical trials, and expert opinions. Patients selected were diagnosed with NMIBC (

AB - Introduction: There have been no randomized controlled trials (RCTs) evaluating the clinical or economic benefit of mitomycin C intravesical therapy vs. radical cystectomy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). We used the Archimedes computational model to simulate RCT comparing radical cystectomy versus intravesical mitomycin C (MMC) therapy to evaluate the clinical and economic outcomes for BCG-refractory NMIBC as well demonstrate the utility of computer based models to simulate a clinical trial. Methods: The Archimedes model was developed to generate a virtual population using the Surveillance Epidemiology and End Results database, other clinical trials, and expert opinions. Patients selected were diagnosed with NMIBC (

U2 - 10.3233/BLC-150020

DO - 10.3233/BLC-150020

M3 - Journal article

VL - 1

SP - 143

EP - 150

JO - Bladder cancer (Amsterdam, Netherlands)

JF - Bladder cancer (Amsterdam, Netherlands)

SN - 2352-3727

IS - 2

ER -